Patents don't make money.
Wow …. LMAO
Perhaps you had better tell Takeda (who acquired TiGenix) that they should apply for a refund of the $10 million Euros they have paid so far for their global patent license fees and of course tell them not to bother paying future royalties for Alifosel, which is now approved in multiple countries ….. then you should call JCR and tell them the same thing
https://www.globenewswire.com/news-...cells-in-the-local-treatment-of-fistulae.html
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
CHF - MSB's Dark Horse with Multi-billion dollar potential, page-152
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |